Arsenic created a serious public health problem in Bangladesh due to its presence in groundwater and dissemination of the toxic effects to millions of people. The scarcity of the treatment options to manage this affected population has made the situation much worse. To find a promising treatment option, this study was undertaken to examine the ameliorating roles of leaf extract (SLE) against arsenic-induced toxic effects in mice. Swiss albino mice were divided into four groups where 'control' group received pure water + normal feed, 'arsenic (As)' group received sodium arsenite (NaAsO)-containing water (10 μg/g body weight/day) + normal feed, 'As+SLE' group received NaAsO-containing water + feed supplemented with SLE (50 µg/g body weight/day) and finally the 'SLE' group received pure water + feed supplemented with SLE. A gradual increase in body weight gain was observed in control mice; however, the body weight gain in As-exposed mice was decreased. This decrease in body weight gain was prevented in As+SLE group mice that received SLE supplemented feed. Arsenic showed a secondary effect by causing enlargement of spleen, kidney and liver of 'As' group mice and this enlargement of the organs was minimized with SLE supplementation. In addition, SLE abrogated arsenic-mediated elevation of serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), uric acid and glucose. These results, therefore, suggest that SLE might have future therapeutic value for preventing or reducing arsenic-induced toxic effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472542PMC
http://dx.doi.org/10.18999/nagjms.79.2.167DOI Listing

Publication Analysis

Top Keywords

toxic effects
16
group received
16
arsenic-induced toxic
12
body weight
12
weight gain
12
effects mice
8
leaf extract
8
received pure
8
pure water
8
normal feed
8

Similar Publications

Erlotinib-induced Perioral Lesions Resembling Scleroderma.

Acta Dermatovenerol Croat

November 2024

Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.

View Article and Find Full Text PDF

Background: Amiodarone, a common antiarrhythmic drug, is known for its severe side effects, including pulmonary toxicity, which involves oxidative stress and apoptosis. Artemisinin, an antimalarial drug, has shown cytoprotective properties by inhibiting oxidative stress and apoptosis. This study investigated the protective effects of artemisinin against amiodarone-induced toxicity in human bronchial epithelial cells (BEAS-2B) and mouse models.

View Article and Find Full Text PDF

HER2-targeted ADC DX126-262 combined with chemotherapy demonstrates superior antitumor efficacy in HER2-positive gastric cancer.

Am J Cancer Res

December 2024

Hangzhou DAC Biotechnology Co., Ltd. No. 369 Qiaoxin Road, Qiantang District, Hangzhou 310018, Zhejiang, China.

Gastric cancer is a common malignant tumor with high incidence and mortality. The overexpression of Human epidermal growth factor receptor 2 (HER2) is associated with increased metastatic potential and poor clinical outcome in gastric cancer. Despite the proven clinical response rates of approved HER2-targeted therapies, including Trastuzumab combined with chemotherapy, their limited long-term clinical benefits and inevitable disease progression still pose significant challenges to the clinical treatment of gastric cancer.

View Article and Find Full Text PDF

Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy.

Drug Des Devel Ther

January 2025

Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (Luvacs), Department of Internal Medicine - Nephrology Section, Leiden University Medical Center, Leiden, the Netherlands.

Recently, avacopan has been approved for the treatment of ANCA-associated vasculitis (AAV). Avacopan is an inhibitor of the C5a-receptor, which plays an important role in chemotaxis and the amplification loop of inflammation in AAV. In the most recent, international guidelines avacopan is recommended as steroid-sparing agents for the management of AAV.

View Article and Find Full Text PDF

Despite recent advances, improvements to long-term survival in metastatic carcinomas, such as pancreatic or ovarian cancer, remain limited. Current therapies suppress growth-promoting biochemical signals, ablate cells expressing tumor-associated antigens, or promote adaptive immunity to tumor neoantigens. However, these approaches are limited by toxicity to normal cells using the same signaling pathways or expressing the same antigens, or by the low frequency of neoantigens in most carcinomas.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!